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Case report: multiple UGT1A1 gene variants
in a patient with Crigler-Najjar syndrome
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Abstract
Background: Inherited unconjugated hyperbilirubinemia is caused by variants in the gene UGT1A1 leading to
Gilbert’s syndrome and Crigler-Najjar syndrome types I and II. These syndromes are differentiated on the basis of
UGT1A1 residual enzymatic activity and its affected bilirubin levels and responsiveness to phenobarbital treatment.
Case presentation: In this report, we present a boy with Crigler-Najjar syndrome type II with high unconjugated
bilirubin levels that decreased after phenobarbital treatment but increased in adolescence. Four different UGT1A1
gene variants have been identified for this patient, of which one is novel (g.11895_11898del) most likely confirming
diagnose molecularly.
Conclusions: The presented case highlights the challenges encountered with the interpretation of molecular data
upon identification of multiple variants in one gene that are causing different degree reducing effect on enzyme
activity leading to several clinical conditions.
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Background
Inherited unconjugated hyperbilirubinemia is caused by
pathogenic variants in the UGT1A1 gene and, depending
on the bilirubin levels, is categorized as Gilbert’s syndrome
(GS; OMIM: 143500), Crigler-Najjar syndrome type I
(CNS-I; OMIM: 218800), or Crigler-Najjar syndrome type
II (CNS-II; OMIM: 606785); the total bilirubin levels
range from 17.1–102.6 μmol/L, 102.6–342 μmol/L, and
342–769.5 μmol/L, respectively [1]. When not appropri-
ately treated, CNS-I is an early lethal condition character-
ized by kernicterus caused by the absence of active
UDP-glucuronosyltransferase 1A1 (UGT1A1). In the case
of CNS-II, UGT1A1 activity is greatly reduced [1].
There are numerous reports on UGT1A1 gene variants
that are related to the aforementioned clinical conditions
[2, 3]. The most common condition is GS which affects
~ 10% of Europeans. As there are cases where it is diffi-
cult to distinguish the disorders caused by pathogenic
variants in the UGT1A1 gene, genetic investigations are
becoming increasingly important [4].
The patient described here has unconjugated hyperbi-
lirubinemia that is responsive to phenobarbital treatment
and carries four genetic variations in the UGT1A1 gene,
one of which is reported for the first time.
Case presentation
The proband is a 17-year-old Caucasian male who first pre-
sented at the neonatal stage with prolonged jaundice with
an unconjugated bilirubin level of 400 μmol/L without
hemolytic anemia data. Following an uneventful pregnancy,
the patient was the first child of non-consanguineous Cau-
casian parents. Due to jaundice and elevated indirect biliru-
bin levels, he was diagnosed with GS soon after delivery as
he had the A(TA)7TAA allele in homozygous state (identi-
fied by fragment analysis as previously described [5]). Dur-
ing his childhood years, the patient did well. He periodically
underwent phenobarbital treatment for the reduction of
bilirubin levels associated with jaundice; the mean bilirubin
levels achieved as the result of these treatments were 100–
200 μmol/L. The patient’s parents had no complaints until
puberty.
After reaching puberty, the boy became severely jaun-
diced and his bilirubin levels increased to 300–
350 μmol/L. However, there were no other complaints,
he was doing well in school and his weight and height
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parameters were according to his age. The boy was re-
ferred to a hepatologist and multiple investigations were
carried out. No pathological findings were observed in
the laboratory analysis and hepatitis viral markers were
negative. Furthermore, there was no evidence of other
inborn errors of metabolism, i.e. organic acidurias and
amino acidurias or changes in the fatty acid profile.
The results of abdominal ultrasound and abdominal MRI
were unremarkable. Procurement of a percutaneous liver
biopsy revealed no pathological findings. Based on isolated
elevation of indirect bilirubin levels from standard labora-
tory investigations, reduced glutathione (0.89 mmol/l; refer-
ence value 1.12–1.216 mmol/l), a glucuronide level in 24-h
urine of up to 102 mg/ml (reference value 430–600 mg/
ml), phenobarbital responsiveness, and no evidence of ker-
nicterus (as the child had no complaints about his health
condition), CNS-II was suspected.
To confirm the CNS-II diagnosis, bidirectional se-
quencing of five exons and exon/intron boundaries of
the gene UGT1A1 (OMIM: 191740) was performed
using previously described primers [6] and a BigDye 3.0
kit (following the manufacturer’s protocol; Applied Bio-
systems, USA). The nomenclature of the identified varia-
tions was identified by using Mutalyzer (https://
mutalyzer.nl/) and assessed sequentially against the Sin-
gle Nucleotide Polymorphism Database (dbSNP;
www.ncbi.nlm.nih.gov/SNP), Exome Aggregation Con-
sortium (ExAC; exac.broadinstitute.org), ClinVar (http://
www.ncbi.nlm.nih.gov/clinvar), and the UGT1A1 variant
database [3]. A search was performed with MEDLINE if
the variation was not found in any of the aforemen-
tioned databases. The biological significance of observed
nucleotide changes located at splice sites was assessed
using the Human Splicing Finder (HSF) 3.0 [7] and
MutationTaster [8].
Four different variants in the UGT1A1 gene were identi-
fied in the patient: g.3664A > C (c.1352A > C, rs3755319);
g.4963_4964TA[7] (c.-53_-52insTA, A(TA)7TAA, UGT
1A1*28, rs8175347); g.5884G > T (c.864 + 5G > T, IVS1 +
5G > T); and g.11895_11898del (c.996+2_996+5del) (refer-
ence sequence NG_033238.1) .
In the ClinVar database, the variant g.4963_4964TA[7]
is described as a variant affecting response to drug treat-
ment. This is the most common variant identified in pa-
tients with GS. The variant g.3664A > C, as reported in
the ClinVar database, causes transient familial neonatal
hyperbilirubinemia (OMIM: 237900). The variant
g.5884G > T located in the first intron has previously
been reported in a patient with CNS-II [9], and from ex-
ome sequencing has been identified only in Europeans
in five alleles (exac.broadinstitute.org). The second in-
tronic variant g.11895_11898del (located in second in-
tron two nucleotides after the second exon) is reported
for the first time (sequence showed in the Fig. 1).
Considering that one of the criteria for evaluating vari-
ant pathogenicity is its frequency in the healthy popula-
tion, 90 healthy individuals from the Genome Database
of the Latvian Population (LGDB), a government-funded
biobank (the principle of LGDB has previously been re-
ported [10]), were randomly selected and screened for
the two lesser-described variants g.5884G > T and
g.11895_11898del. The screened variants were not iden-
tified for any of the selected individuals. In order to
identify variant segregation in the family, the parents
were assessed for all the variants (Fig. 2). Both parents
demonstrated normal-range levels of bilirubin from mul-
tiple measurements.
The intronic variants not mentioned in the ClinVar
database were annotated according to ACMG standards
and guidelines [11]. Both variants are classified as likely
pathogenic (for variant g.5884G > T – fulfilled criteria
PM2, PM3, PP3, PP4, PP5; for variant g.11895_11898del
– fulfilled criteria PM2, PM3, PP3, PP4; Table 1).
Discussion and conclusions
Three inherited disorders leading to unconjugated
hyperbilirubinemia have been identified. They are cate-
gorized depending on the bilirubin levels, phenobarbital
responsiveness, and clinical picture.
We present here a 17-year-old male with CNS-II who
has significant hyperbilirubinemia that decreases after
phenobarbital intake and some UGT1A1 activity con-
firmed by glucuronide traces in his urine. He carries four
genetic variants in the UGT1A1 gene; one reported for
the first time. Phenobarbital responsiveness and the ab-
sence of kernicterus are described as criteria to discrim-
inate CNS-I and CNS-II [1, 12]. However, atypical cases
have also been reported. Duhamel et al. described a
25-year-old male with total bilirubin levels suggestive of
CNS-I but without any neurological changes and pheno-
barbital unresponsiveness; no molecular investigations
were carried out for that particular patient [13]. Chala-
sani et al. reported a CNS-II patient who developed ker-
nicterus after laparoscopic surgery, leading to hematoma
and resulting in a more significant increase in bilirubin
production; the patient had three mutations:
A(TA)7TAA in homozygous state and c.1391A > C in
heterozygous state [14].
With regard to genotype/phenotype correlation in the
case of variants of UGT1A1, Kadakol et al. proposed
how to differentiate between CNS-I and CNS-II based
upon molecular findings [15]. CNS-I results from gen-
etic lesions that cause the premature truncation of
UGT1A1, also caused by splice defects or substitution of
critical amino acid residues, whereas CNS-II is caused
by the substitution of one amino acid residue that mark-
edly reduces without abolishing the catalytic activity of
the enzyme [15]. Li et al. analyzed CNS-II patients in
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the Chinese population and discovered the existence of
a genotype/phenotype correlation [16]. Patients homozy-
gous for both variations G71R and Y486D had a biliru-
bin level > 200 μmol/L, but patients with total bilirubin
levels ranging from 102.6 to 200 μmol/L carried a
broader spectrum of UGT1A1 variants [16]. However,
due to a different variant spectrum, these data are not
attributable to Europeans.
Our described patient has four different molecular vari-
ants. This is the first reported case of four variants in one
patient; previous reports have identified three variants in a
single patient [17–19]. It is not clear how multiple variants
in the UGT1A1 gene affect the clinical status. Kadakol et
al. described four different gender and age families with
identified multiple genetic variants in patients with un-
conjugated hyperbilirubinemia (> 100 μmol/L) and con-
cluded based on the high frequency of UGT1A1 promoter
variant A(TA)7TAA that further examination of the
structural variants in the gene should be conducted for
patients with hyperbilirubinemia as it could help find
more severe phenotypes [15]. The variant A(TA)7TAA in
homozygous state leads to 70% reduction in UGT1A1 ex-
pression compared to A(TA)6TAA carriers [20], and the
presence of additional variants is likely to affect the en-
zyme activity even more [15].
Our patient has the rs3755319 variant that could explain
his neonatal hyperbilirubinemia, the A(TA)7TAA variant
that could contribute to his prolonged hyperbilirubinemia,
and two other variants, one of which (c.864 + 5G > T) has
been reported in a compound heterozygous state in preg-
nant women with variant c.1175C > T in patients with
CNS-II [9]. The other variant (g.11895_11898del) is re-
ported for the first time and according to the ACMG
guidelines could be classified as a likely pathogenic variant
(see Table 1). Unfortunately, no functional studies for the
identified variants have been performed as UGT1A1 is
Fig. 1 Electropherogram of the identified novel variant NG_033238.1: g.11895_11898del (c.996+2_996+5del) in case patient. In the first row
showed reference sequence, in square given deleted nucleotides
Fig. 2 Pedigree of the family with Crigler-Najjar syndrome type II showing segregation of the identified genetic variants in the gene UGT1A1
(reference sequence NG_033238.1)
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expressed only in the liver [21] and there were no indica-
tions for a liver biopsy, no RNA sample was available and
in vitro study as presented by Gupta et al. were not per-
formed [22]. Splice site mutations in UGT1A1 were first
reported in CNS-I [23], then reported in a subsequent
mutation classification to be causing CNS-I [2]. However,
although the total bilirubin levels of our patient in adoles-
cence correspond to CNS-I, he is responsive to phenobar-
bital treatment and to date there are no signs of
kernicterus, thus classifying as CNS-II. According to the
ACMG guidelines, functional studies provide likely patho-
genic criteria for the interpretation of the classification of
unreported splice site variants. In the case of our patient,
functional studies were not conducted. However, previous
studies have shown that functional studies correlate well
with pathogenicity prediction tools in case of UGT1A1 al-
lelic variants [22], but to our knowledge there is no com-
putational tool for analysing multiple allelic variant effect
on one allele. In our study computation tools were used
analysing effect of single allelic variant – here, Mutation-
Taster and HSF predicted that the variation breaks the
wild type splice site and as the variant is localized in the
intron after exon 2, then it would affect all transcripts of
the gene. Also based on family segregation analysis clinical
symptoms could be caused by both variants
g.11895_11898del and c.864 + 5G > T located in trans pos-
ition, because for both parents one variant was identified
but without remarkable changes in the bilirubin level.
The reported case demonstrates that it is not always
possible to distinguish between CNS-I and CNS-II based
on molecular findings and for patients with elevated un-
conjugated bilirubin level if confirming most common
genotype for GS (homozygote for (A(TA)7TAA allele)
should be performed full UGT1A1 sequencing if level of
unconjugated bilirubin is atypically high Furthermore,
wider opportunities present a greater challenge concern-
ing interpretation, as encountered by our group when
identifying an unreported variant.
Study limitation is missing functional studies of mul-
tiple variant effects on UGT1A1 expression level.
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Passuello et al., 2009 None
Total score Likely pathogenic Likely pathogenic
aAs identified variant is indel frequency, should be evaluated with caution
b ΔCT – if difference between consensus value for wild type and mutated
variantis below − 10% it is considered that splice site is broken [7]
cif maximal entropy is below − 30%, it is considered that splice site is
broken [7]
Gailite et al. BMC Pediatrics  (2018) 18:317 Page 4 of 5
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Scientific Laboratory of Molecular Genetics, Riga Stradiņš University,
Dzirciema Street 16, Riga LV 1007, Latvia. 2Children’s Clinical University
Hospital, Vienibas gatve 45, Riga LV 1004, Latvia.
Received: 10 October 2017 Accepted: 17 September 2018
References
1. Arias IM, Gartner LM, Cohen M, Ezzer JB, Levi AJ. Chronic nonhemolytic
unconjugated hyperbilirubinemia with glucuronyl transferase deficiency.
Clinical, biochemical, pharmacologic and genetic evidence for
heterogeneity. Am J Med. 1969;47(3):395–409.
2. Kadakol A, Ghosh SS, Sappal BS, Sharma G, Chowdhury JR, Chowdhury NR.
Genetic lesions of bilirubin uridine-diphosphoglucuronate
glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert
syndromes: correlation of genotype to phenotype. Hum Mutat. 2000;16(4):
297–306.
3. Canu G, Minucci A, Zuppi C, Capoluongo E. Gilbert and Crigler Najjar
syndromes: an update of the UDP-glucuronosyltransferase 1A1 (UGT1A1)
gene mutation database. Blood Cells Mol Dis. 2013;50(4):273–80.
4. Maruo Y, Nakahara S, Yanagi T, Nomura A, Mimura Y, Matsui K, Sato H,
Takeuchi Y. Genotype of UGT1A1 and phenotype correlation between
Crigler-Najjar syndrome type II and Gilbert syndrome. J Gastroenterol
Hepatol. 2016;31(2):403–8.
5. Lin JP, O'Donnell CJ, Schwaiger JP, Cupples LA, Lingenhel A, Hunt SC, Yang
S, Kronenberg F. Association between the UGT1A1*28 allele, bilirubin levels,
and coronary heart disease in the Framingham heart study. Circulation.
2006;114(14):1476–81.
6. Costa E, Vieira E, Martins M, Saraiva J, Cancela E, Costa M, Bauerle R, Freitas
T, Carvalho JR, Santos-Silva E, et al. Analysis of the UDP-
glucuronosyltransferase gene in Portuguese patients with a clinical
diagnosis of Gilbert and Crigler-Najjar syndromes. Blood Cells Mol Dis. 2006;
36(1):91–7.
7. Desmet FO, Hamroun D, Lalande M, Collod-Beroud G, Claustres M, Beroud
C. Human splicing finder: an online bioinformatics tool to predict splicing
signals. Nucleic Acids Res. 2009;37(9):e67.
8. Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation
prediction for the deep-sequencing age. Nat Methods. 2014;11, edn. United
States:361–2.
9. Passuello V, Puhl AG, Wirth S, Steiner E, Skala C, Koelbl H, Kohlschmidt N.
Pregnancy outcome in maternal Crigler-Najjar syndrome type II: a case report
and systematic review of the literature. Fetal Diagn Ther. 2009;26(3):121–6.
10. Ignatovica V, Latkovskis G, Peculis R, Megnis K, Schioth HB, Vaivade I,
Fridmanis D, Pirags V, Erglis A, Klovins J. Single nucleotide polymorphisms
of the purinergic 1 receptor are not associated with myocardial infarction in
a Latvian population. Mol Biol Rep. 2012;39(2):1917–25.
11. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde
M, Lyon E, Spector E, et al. Standards and guidelines for the interpretation
of sequence variants: a joint consensus recommendation of the American
College of Medical Genetics and Genomics and the Association for
Molecular Pathology. Genet Med. 2015;17(5):405–23.
12. Seppen J, Bosma PJ, Goldhoorn BG, Bakker CT, Chowdhury JR, Chowdhury
NR, Jansen PL, Oude Elferink RP. Discrimination between Crigler-Najjar type I
and II by expression of mutant bilirubin uridine diphosphate-
glucuronosyltransferase. J Clin Invest. 1994;94(6):2385–91.
13. Duhamel G, Blanckaert N, Metreau JM, Preaux AM, Bouvry M, Fevery J,
Berthelot P. An unusual case of Crigler-Najjar disease in the adult.
Classification into types I and II revisited. J Hepatol. 1985;1(1):47–53.
14. Chalasani N, Chowdhury NR, Chowdhury JR, Boyer TD. Kernicterus in an
adult who is heterozygous for Crigler-Najjar syndrome and homozygous for
Gilbert-type genetic defect. Gastroenterology. 1997;112(6):2099–103.
15. Kadakol A, Sappal BS, Ghosh SS, Lowenheim M, Chowdhury A, Chowdhury
S, Santra A, Arias IM, Chowdhury JR, Chowdhury NR. Interaction of coding
region mutations and the Gilbert-type promoter abnormality of the UGT1A1
gene causes moderate degrees of unconjugated hyperbilirubinaemia and
may lead to neonatal kernicterus. J Med Genet. 2001;38(4):244–9.
16. Li L, Deng G, Tang Y, Mao Q. Spectrum of UGT1A1 variations in Chinese
patients with Crigler-Najjar syndrome type II. PLoS One. 2015;10(5):
e0126263.
17. Tesapirat L, Nilyanimit P, Wanlapakorn N, Poovorawan Y. Compound
heterozygosity of a novel exon 3 frameshift (p.R357P fs*24) mutation and
Y486D mutation in exon 5 of the UGT1A1 gene in a Thai infant with
Crigler-Najjar syndrome type 2. Genet Mol Res. 2015;14(2):3293–9.
18. D'Angelo R, Rinaldi C, Donato L, Nicocia G, Sidoti A. The combination of new
missense mutation with [a(TA)7TAA] dinucleotide repeat in UGT1A1 gene
promoter causes Gilbert's syndrome. Ann Clin Lab Sci. 2015;45(2):202–5.
19. Zheng B, Hu G, Yu J, Liu Z. Crigler-Najjar syndrome type II in a Chinese boy
resulting from three mutations in the bilirubin uridine 5′-diphosphate-
glucuronosyltransferase (UGT1A1) gene and a family genetic analysis. BMC
Pediatr. 2014;14:267.
20. Bosma PJ, Seppen J, Goldhoorn B, Bakker C, Oude Elferink RP, Chowdhury
JR, Chowdhury NR, Jansen PL. Bilirubin UDP-glucuronosyltransferase 1 is the
only relevant bilirubin glucuronidating isoform in man. J Biol Chem. 1994;
269(27):17960–4.
21. Ritter JK, Kessler FK, Thompson MT, Grove AD, Auyeung DJ, Fisher RA.
Expression and inducibility of the human bilirubin UDP-
glucuronosyltransferase UGT1A1 in liver and cultured primary hepatocytes:
evidence for both genetic and environmental influences. Hepatology. 1999;
30(2):476–84.
22. Gupta N, Benjamin M, Kar A, Munjal SD, Sarangi AN, Dalal A, Aggarwal R.
Identification of promotor and Exonic variations, and functional
characterization of a splice site mutation in Indian patients with
unconjugated hyperbilirubinemia. PLoS One. 2015;10(12):e0145967.
23. Gantla S, Bakker CT, Deocharan B, Thummala NR, Zweiner J, Sinaasappel M,
Roy Chowdhury J, Bosma PJ, Roy Chowdhury N. Splice-site mutations: a
novel genetic mechanism of Crigler-Najjar syndrome type 1. Am J Hum
Genet. 1998;62(3):585–92.
Gailite et al. BMC Pediatrics  (2018) 18:317 Page 5 of 5
